INNO

Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. has identified basic scientific mechanisms that promise torevolutionize pulmonary drug delivery. This proprietary technologyuses a stream of purified air to deliver medications deep into thepulmonary system. It is considered superior to other drug deliverysystems because it rapidly administers aerosolized drugs to thelin...

Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting

NEW YORK--(BUSINESS WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today announced that interim data from a Phase Itrial of INNO-406, an orally bioavailable dual Bcr-Abl andLyn-kinase inhibitor for Gleevec(R)-resistant ortreatment-intolerant chronic myelogenous leukemia, will bepresented at the 43rd American Society of Clinical Oncology AnnualMeeting. The meeting takes pl...

FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations, FDA Regulations

Is FDA Equipped to Meet Pace of Innovations and a Health ConsciousPublic? WASHINGTON, April 30, 2007 /PRNewswire-USNewswire/ -- The Foodand Drug Administration (FDA) must adapt to the most significantchanges in the history of healthcare, Commissioner Andrew vonEschenbach told attendees at the Food and Drug Law Institute's 50thAnnual Conference April 12 in Bethesda, Md. FDA must fin...

Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma

Adding MabThera to first line chemotherapy significantlyincreases patients_ overall survival BASEL, Switzerland (21 May, 2007) _ In a study publishedyesterday in the Journal of Clinical Oncology, MabThera (rituximab)plus chemotherapy (MCP*) was shown to significantly improvesurvival in patients with follicular lymphoma (FL) compared tochemotherapy alone.1 Follicular lymphoma is the...

Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference

PETALUMA, Calif.--(BUSINESS WIRE)--May 14, 2007 - Oculus InnovativeSciences, Inc. (NASDAQ:OCLS) today reported that its MicrocynTechnology was the subject of a poster presentation at the EuropeanWound Management Association (EWMA) conference that was held inGlasgow, Scotland this past week. The poster, entitled Clinical Results About an AntimicrobialSolution in the Treatment of Infected C...

Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program

NEW YORK--(BUSINESS WIRE)--Apr 18, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) announced data from preclinical evaluation of thecompany's drug candidate INNO-206, a doxorubicin prodrug fortreatment of a variety of tumor types. Researchers found thatINNO-206, a form of doxorubicin that attaches to circulatingalbumin and becomes activated once located at the tumor site, ismuch better to...

Innovive Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) today announced that data from preclinicalstudies of INNO-406, a potent oral dual Bcr-Abl and Lyn-kinaseinhibitor for Gleevec-resistant or treatment-intolerant chronicmyelogenous leukemia, will be presented at the American Associationfor Cancer Research Annual Meeting. The meeting takes place April14-18, 20...

DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy

EVRY, France, April 12, 2007 /PRNewswire/ -- DNA TherapeuticsS.A. an emerging pharmaceutical company specialized in innovativecancer therapy announces today the elucidation of a new mechanismof action and the identification of a biomarker of itsfirst-in-class antitumoral lead molecule Dbait. It will bepresented at the forecoming American Association for CancerResearch annual meeting 2007...

Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 10, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) today announced that interim data from a Phase Itrial of INNO-406, an orally bioavailable dual Bcr-Abl andLyn-kinase inhibitor for Gleevec-resistant or treatment-intolerantchronic myelogenous leukemia, will be presented at the AmericanAssociation for Cancer Research Annual Meeting. Additionally,preclinical...